<DOC>
	<DOC>NCT00745875</DOC>
	<brief_summary>The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone</brief_summary>
	<brief_title>ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy Patients that meet one of the following criteria: progressed following one prior platinumbased chemotherapy regimen for locally advanced or metastatic disease; progressed within 6 months of adjuvant platinumbased chemotherapy Life expectancy of &gt; 12 weeks Prior treatment with pemetrexed in the last 12 months. Prior therapy with an ET receptor antagonist Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Phase II</keyword>
	<keyword>ZD4054</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>